PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33203790-0	2020	Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.	Sorafenib	48-57	kinesin family member 14	Mus musculus	10-15	
33203790-4	2020	We identified KIF14 as an oncogene involved in the acquired resistance to sorafenib in HCC and investigated its potential as a target for reversing this resistance.	Sorafenib	74-83	kinesin family member 14	Mus musculus	14-19	
33203790-5	2020	Sustained exposure of resistant HCC cells to sorafenib activated the AKT pathway, which in turn upregulated KIF14 expression by increasing expression of the transcription factor ETS1.	Sorafenib	45-54	kinesin family member 14	Mus musculus	108-113	
33203790-6	2020	Silencing KIF14 reversed the acquired resistance to sorafenib by inhibiting AKT activation and downregulating ETS1 expression by blocking the AKT-ETS1-KIF14 positive feedback loop.	Sorafenib	52-61	kinesin family member 14	Mus musculus	10-15	
33203790-6	2020	Silencing KIF14 reversed the acquired resistance to sorafenib by inhibiting AKT activation and downregulating ETS1 expression by blocking the AKT-ETS1-KIF14 positive feedback loop.	Sorafenib	52-61	kinesin family member 14	Mus musculus	151-156	
33203790-8	2020	These results demonstrate that targeting KIF14 could be an effective means of reversing sorafenib failure or strengthening sorafenib"s antitumor effects.	Sorafenib	88-97	kinesin family member 14	Mus musculus	41-46